Literature DB >> 6601649

In-vitro susceptibility of thirty strains of Haemophilus ducreyi to several antibiotics including six cephalosporins.

M J Sanson-Le Pors, I Casin, M Ortenberg, Y Perol.   

Abstract

We have studied the in-vitro susceptibility of 30 strains of Haemophilus ducreyi to 22 antibacterial agents. Twenty-seven strains produced a beta-lactamase that had an isoelectric point similar to the isoelectric point of the TEM 1 type beta-lactamase produced by pSF 2124. Except for cefamandole, the 30 strains had similar susceptibilities to the different cephalosporins, cefotaxime being the most active compound. Twenty-two isolates were resistant to tetracycline and doxycycline; minimal inhibitory concentration (MIC) of minocycline was 4 mg/l for all the strains. One isolate was resistant to chloramphenicol (MIC = 16 mg/l). All strains were relatively resistant to colistin and nalidixic acid, and susceptible to streptomycin, kanamycin, gentamicin, erythromycin, rifampicin and vancomycin.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6601649     DOI: 10.1093/jac/11.3.271

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  9 in total

Review 1.  Antimicrobial susceptibility of Haemophilus ducreyi.

Authors:  Y Dangor; R C Ballard; S D Miller; H J Koornhof
Journal:  Antimicrob Agents Chemother       Date:  1990-07       Impact factor: 5.191

2.  Plasmid-mediated aminoglycoside phosphotransferases in Haemophilus ducreyi.

Authors:  M J Sanson-le Pors; I M Casin; E Collatz
Journal:  Antimicrob Agents Chemother       Date:  1985-08       Impact factor: 5.191

3.  Antimicrobial susceptibilities of southern African isolates of Haemophilus ducreyi.

Authors:  Y Dangor; S D Miller; F da L Exposto; H J Koornhof
Journal:  Antimicrob Agents Chemother       Date:  1988-09       Impact factor: 5.191

4.  In vitro activities of U-63366, a spectinomycin analog; roxithromycin (RU 28965), a new macrolide antibiotic; and five quinolone derivatives against Haemophilus ducreyi.

Authors:  M J Sanson-Le Pors; I M Casin; M C Thebault; G Arlet; Y Perol
Journal:  Antimicrob Agents Chemother       Date:  1986-09       Impact factor: 5.191

Review 5.  Amoxicillin/clavulanic acid. An update of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  P A Todd; P Benfield
Journal:  Drugs       Date:  1990-02       Impact factor: 9.546

6.  Comparison of the in vitro activities of various parenteral and oral antimicrobial agents against endemic Haemophilus ducreyi.

Authors:  K E Aldridge; C Cammarata; D H Martin
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

7.  In vitro susceptibilities of isolates of Haemophilus ducreyi from Thailand and the United States to currently recommended and newer agents for treatment of chancroid.

Authors:  J S Knapp; A F Back; A F Babst; D Taylor; R J Rice
Journal:  Antimicrob Agents Chemother       Date:  1993-07       Impact factor: 5.191

8.  Correlation between in vitro antimicrobial susceptibilities and beta-lactamase plasmid contents of isolates of Haemophilus ducreyi from the United States.

Authors:  M Motley; S K Sarafian; J S Knapp; A A Zaidi; G Schmid
Journal:  Antimicrob Agents Chemother       Date:  1992-08       Impact factor: 5.191

9.  Biotypes, serotypes, and susceptibility to antibiotics of 60 Haemophilus influenzae strains from genitourinary tracts.

Authors:  I Casin; M J Sanson-Le Pors; A Felten; Y Perol
Journal:  Genitourin Med       Date:  1988-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.